Oral spironolactone improves acne vulgaris and reduces sebum excretion

Publisher Website
Google Scholar
Abstract
In a consecutive series of 36 male and female patients with severe acne, the effect of 3 mo. treatment with placebo or spironolactone (50-200 mg daily) on sebum excretion and clinical and endocrine status was evaluated double-blind. Patients (26) completed the study. Abnormal free androgen indices were found in 27% of the original 19 female subjects. Spironolactone reduced sebum excretion in all female subjects, but there was no correlation between sebum response and androgen status. The clinical response was dose-dependent, with maximum subjective and objective benefit when spironolactone doses of 150-200 mg were used.

This publication has 14 references indexed in Scilit: